Leo Marx
Adc Research & Technologies Head Debiopharm
In 2017, Leo joined Debiopharm as medicinal chemist to work on the development of new linker technologies and their applications to novel ADC products. Before this, in 2015 he was at Bayer (Wuppertal) for industrial postdoctoral work focusing on the medicinal chemistry & bioconjugation of linkers containing KSP inhibitors. Leo completed his PhD studies at the University of Oxford, focusing on the total synthesis of lactone containing cytotoxic natural products.
Seminars
Tuesday 24th February 2026
Contextualising Trifecta ADC Design & Advancing Next-Generation Branched Linker ADC Development
2:30 pm
- Applying a trifecta approach to design a fit-for-purpose linker for haematologic ADCs, with preclinical insights from Debio-1562M incorporating MLINKSELECT DM1
- Developing and implementing branched linker technology for next-generation dual payload ADCs in solid tumours
- Recapping lessons learned in advancing high-DAR ADCs from discovery to the clinic
